唾液中ラクトフェリン測定の臨床応用とその意義に関する研究

取得学位 : 博士（医学）, 学位授与番号 : 医博乙第1050号, 学位授与年月日：平成1年6月7日,学位授与年：198

膵液中のPlugの分析とその臨床的意義にかんする研究

金沢大学がん研究所研究課題/領域番号:62770458, 研究期間(年度):1987出典：研究課題「膵液中のPlugの分析とその臨床的意義にかんする研究」課題番号62770458（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-62770458/）を加工して作

Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease

The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone